Regeneron and Sanofi are cutting the price they charge pharmacy benefit manager Express Scripts for their cholesterol medicine, Praluent. In return, Express Scripts will remove almost all restrictions on the medicine, and make it cheaper for patients.
The future of the expensive new cholesterol drugs largely depends on the results of the Sanofi/Regeneron ODYSSEY Outcomes trial coming out next month.